This morning on "Squawk Box" and "Squawk on the Street" I reported on a new study showing that a simple blood test might predict whether you will develop Alzheimer's Disease. The report, which appears in the scientific,peer-reviewed journal "Nature Medicine"says that the patent-pending test developed by the privately-held company Satoris was 90% accurate at pegging future Alzheimer's patients on average two-and-a-half years before being diagnosed.
Over the weekend I spoke by phone with Patrick Lynn, the CEO of Satoris(rooted in the Japanese/Buddhist word, satori, which means "enlightenment"), about what this means for his company and the test. And before this opens the floodgates of my inbox for PR-people who want to pitch stories on privately-held companies, I want to make it clear that this story is an exception to our rule.
Typically, I do not do stories on companies that are not publicly traded. It's part of our editorial mandate at CNBC. But, in this case, the data were so compelling and the idea of an Alzheimer's test potentially so groundbreaking, that we decided to cover the story. In addition, the company and a leading, independent Alzheimer's expert told us that if the test comes to market that it would help identify ideal candidates for the dozens of ongoing Alzheimer's drug clinical trials at publicly-traded pharmaceutical and biotech companies--Lilly, Wyeth, Memory Pharmaceuticals and Elan, just to name a few.